• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性出血性毛细血管扩张症:意大利首例奠基者效应的证明;ACVRL1 c.289_294del 变异源于 200 年前的贝加莫地区。

Hereditary hemorrhagic telangiectasia: First demonstration of a founder effect in Italy; the ACVRL1 c.289_294del variant originated in the country of Bergamo 200 years ago.

机构信息

General Biology and Medical Genetics Unit, Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Laboratory of Bioinformatics, Fondazione IRCCS Casa Sollievo della Sofferenza-Mendel, San Giovanni Rotondo (FG), Italy.

出版信息

Mol Genet Genomic Med. 2022 Aug;10(8):e1972. doi: 10.1002/mgg3.1972. Epub 2022 May 27.

DOI:10.1002/mgg3.1972
PMID:35620871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9356557/
Abstract

BACKGROUND

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disorder, affecting 1:5000 individuals worldwide. All the genes associated to the disease (ENG, ACVRL1, SMAD4, GDF2) belong to the TGF-β/BMPs signaling pathway. We found 19 HHT unrelated families, coming from a Northern Italy region and sharing the ACVRL1 in-frame deletion c.289_294del (p.H97_N98).

METHODS

To test the hypothesis of a founder effect, we analyzed 88 subjects from 19 families (66 variant carriers, showing clinical signs of HHT, and 22 non-carriers, unaffected) using eight microsatellite markers within 3.7 Mb around the ACVRL1 locus. After the haplotype reconstruction, age estimation of the variant was carried out.

RESULTS

We observed a common disease haplotype in 16/19 families, while three families showed evidence of recombination around the ACVRL1 locus. The subsequent age estimation analyses suggested that the mutation occurred about 8 generations ago, corresponding to about 200 years ago. We also present novel in silico and modeling data supporting the variant pathogenicity: the deletion alters the protein stability and removes the unique extracellular glycosylation site.

CONCLUSION

We have demonstrated, for the first time, a "founder effect" for a HHT pathogenic variant in Italy.

摘要

背景

遗传性出血性毛细血管扩张症(HHT)是一种常染色体显性血管疾病,影响全球每 5000 人中的 1 人。与该疾病相关的所有基因(ENG、ACVRL1、SMAD4、GDF2)均属于 TGF-β/BMPs 信号通路。我们发现了来自意大利北部地区的 19 个与 HHT 无关的家族,这些家族都携带有 ACVRL1 框内缺失 c.289_294del(p.H97_N98)。

方法

为了验证存在 founder 效应的假设,我们使用 8 个微卫星标记分析了 19 个家族的 88 名受试者(66 名变异携带者,表现出 HHT 的临床症状,22 名非携带者,未受影响)。在构建单体型后,对变异的年龄进行了估计。

结果

我们观察到 16/19 个家族存在共同的疾病单体型,而 3 个家族在 ACVRL1 基因座周围显示出重组的证据。随后的年龄估计分析表明,该突变发生在大约 8 代之前,约 200 年前。我们还提供了新的计算机模拟和建模数据,支持该变异的致病性:缺失改变了蛋白的稳定性并去除了独特的细胞外糖基化位点。

结论

我们首次在意大利证明了 HHT 致病性变异存在“founder 效应”。

相似文献

1
Hereditary hemorrhagic telangiectasia: First demonstration of a founder effect in Italy; the ACVRL1 c.289_294del variant originated in the country of Bergamo 200 years ago.遗传性出血性毛细血管扩张症:意大利首例奠基者效应的证明;ACVRL1 c.289_294del 变异源于 200 年前的贝加莫地区。
Mol Genet Genomic Med. 2022 Aug;10(8):e1972. doi: 10.1002/mgg3.1972. Epub 2022 May 27.
2
Mutation analysis in Norwegian families with hereditary hemorrhagic telangiectasia: founder mutations in ACVRL1.挪威遗传性出血性毛细血管扩张症家族的突变分析:ACVRL1中的奠基者突变
Clin Genet. 2016 Feb;89(2):182-6. doi: 10.1111/cge.12612. Epub 2015 Jun 5.
3
[Genetic diagnostics of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease)].遗传性出血性毛细血管扩张症(奥斯勒-韦伯-伦杜病)的基因诊断
Orv Hetil. 2019 May;160(18):710-719. doi: 10.1556/650.2019.31380.
4
Mutational and clinical spectrum of Japanese patients with hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症日本患者的突变和临床谱。
BMC Med Genomics. 2021 Dec 6;14(1):288. doi: 10.1186/s12920-021-01139-y.
5
Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence.遗传性出血性毛细血管扩张症患者的临床和分子特征:来自 HHT 卓越中心的经验。
Am J Med Genet A. 2021 Jul;185(7):1981-1990. doi: 10.1002/ajmg.a.62193. Epub 2021 Mar 26.
6
Curaçao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2).库拉索遗传性出血性毛细血管扩张症诊断标准高度预测 ENG 或 ACVRL1 (HHT1 和 HHT2)中的致病性变异。
Genet Med. 2020 Jul;22(7):1201-1205. doi: 10.1038/s41436-020-0775-8. Epub 2020 Apr 17.
7
Identification of a Novel ACVRL1 Gene Mutation (c.100T>A, p.Cys34Ser) in a Japanese Patient with Possible Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease).在一名可能患有遗传性出血性毛细血管扩张症(Osler-Weber-Rendu 病)的日本患者中鉴定出一种新型 ACVRL1 基因突变(c.100T>A,p.Cys34Ser)。
Acta Med Okayama. 2020 Apr;74(2):165-169. doi: 10.18926/AMO/58276.
8
Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia.ACVRL1 序列变异在遗传性出血性毛细血管扩张症的肝血管畸形中起着关键作用。
Orphanet J Rare Dis. 2020 Sep 22;15(1):254. doi: 10.1186/s13023-020-01533-2.
9
Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.ENG、ACVRL1 和 SMAD4 基因突变与遗传性出血性毛细血管扩张症的临床表现:来自乌普萨拉大学医院奥尔斯勒病中心的经验。
Ups J Med Sci. 2018 Sep;123(3):153-157. doi: 10.1080/03009734.2018.1483452. Epub 2018 Sep 25.
10
Variant analysis in Chinese families with hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症家系的变异分析。
Mol Genet Genomic Med. 2019 Sep;7(9):e893. doi: 10.1002/mgg3.893. Epub 2019 Aug 10.

引用本文的文献

1
Hereditary Hemorrhagic Telangiectasia in Pediatric Age: Focus on Genetics and Diagnosis.儿童期遗传性出血性毛细血管扩张症:聚焦遗传学与诊断
Pediatr Rep. 2023 Feb 10;15(1):129-142. doi: 10.3390/pediatric15010011.

本文引用的文献

1
Founder Effects in Hereditary Hemorrhagic Telangiectasia.遗传性出血性毛细血管扩张症中的奠基者效应
J Clin Med. 2021 Apr 14;10(8):1682. doi: 10.3390/jcm10081682.
2
Inferring the molecular and phenotypic impact of amino acid variants with MutPred2.使用 MutPred2 推断氨基酸变异的分子和表型影响。
Nat Commun. 2020 Nov 20;11(1):5918. doi: 10.1038/s41467-020-19669-x.
3
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia.遗传性出血性毛细血管扩张症诊断与管理的第二版国际指南。
Ann Intern Med. 2020 Dec 15;173(12):989-1001. doi: 10.7326/M20-1443. Epub 2020 Sep 8.
4
The mutational constraint spectrum quantified from variation in 141,456 humans.从 141456 名人类个体的变异中量化的突变约束谱。
Nature. 2020 May;581(7809):434-443. doi: 10.1038/s41586-020-2308-7. Epub 2020 May 27.
5
VarSome: the human genomic variant search engine.VarSome:人类基因组变异搜索引擎。
Bioinformatics. 2019 Jun 1;35(11):1978-1980. doi: 10.1093/bioinformatics/bty897.
6
SWISS-MODEL: homology modelling of protein structures and complexes.SWISS-MODEL:蛋白质结构和复合物的同源建模。
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303. doi: 10.1093/nar/gky427.
7
Mutation analysis in Norwegian families with hereditary hemorrhagic telangiectasia: founder mutations in ACVRL1.挪威遗传性出血性毛细血管扩张症家族的突变分析:ACVRL1中的奠基者突变
Clin Genet. 2016 Feb;89(2):182-6. doi: 10.1111/cge.12612. Epub 2015 Jun 5.
8
MutationTaster2: mutation prediction for the deep-sequencing age.MutationTaster2:深度测序时代的突变预测
Nat Methods. 2014 Apr;11(4):361-2. doi: 10.1038/nmeth.2890.
9
Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.BRCA1基因环状结构域中一个意大利始祖突变的特征分析
PLoS One. 2014 Feb 6;9(2):e86924. doi: 10.1371/journal.pone.0086924. eCollection 2014.
10
ClinVar: public archive of relationships among sequence variation and human phenotype.ClinVar:序列变异与人类表型之间关系的公共档案。
Nucleic Acids Res. 2014 Jan;42(Database issue):D980-5. doi: 10.1093/nar/gkt1113. Epub 2013 Nov 14.